Novel Endolysin to Selectively Manage Antimicrobial Resistant S. aureus in Wound Biofilms

本博士研究的目的是确定抗生素耐药（AMR）S的贡献。金黄色葡萄球菌对皮肤老化和慢性伤口的作用，同时测试了一种新型金黄色葡萄球菌的选择性和功效。金黄色葡萄球菌靶向内溶素技术用于管理AMR S.金黄色皮肤/伤口感染。博士项目将涉及患者样本的分析，以及在威尔金森博士/哈德曼教授和托马斯教授的小组内进行的详细的机械实验。学生还将与Cica Biomedical进行行业实习，以协助重要的临床前研究。这个博士项目涉及到与Micreos Pharma（过去2年直接资助40万英镑）研究新型内溶素的工作计划，以及国家生物膜创新中心（FTMA和POC奖2021-2022）的先前赠款，这些拨款为该学生提供了重要的试点数据。船体大学和船体约克医学院也支持了一个匹配资助的学生名额，这将与NBIC的学生名额密切配合。

The purpose of this PhD studentship is to determine the contribution of antimicrobial resistant (AMR) S. aureus to skin ageing and chronic wounds, alongside testing the selectivity and efficacy of a novel S. aureus-targeted endolysin technology for the management of AMR S. aureus skin/wound infections. The PhD project will involve analysis of patient samples, alongside detailed mechanistic experiments carried out within the groups of Dr Wilkinson/Prof Hardman and Prof Thomas. The student will also undertake an industry placement with Cica Biomedical to assist with important pre-clinical studies. This PhD project relates to a program of work investigating novel endolysins with Micreos Pharma (£400K direct funding over last 2 years), and previous grants from the National Biofilms Innovation Centre (FTMA and POC awards 2021-2022) that have generated important pilot data for this studentship. A match-funded studentship has also been supported by the University of Hull and Hull York Medical School, which will closely align to the NBIC studentship.